ES3048696T3 - Ror1 antibodies - Google Patents

Ror1 antibodies

Info

Publication number
ES3048696T3
ES3048696T3 ES18742575T ES18742575T ES3048696T3 ES 3048696 T3 ES3048696 T3 ES 3048696T3 ES 18742575 T ES18742575 T ES 18742575T ES 18742575 T ES18742575 T ES 18742575T ES 3048696 T3 ES3048696 T3 ES 3048696T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18742575T
Other languages
English (en)
Spanish (es)
Inventor
Amit Nathwani
Satyen Gohil
Peruta Marco Della
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES3048696T3 publication Critical patent/ES3048696T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18742575T 2017-07-05 2018-07-05 Ror1 antibodies Active ES3048696T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1

Publications (1)

Publication Number Publication Date
ES3048696T3 true ES3048696T3 (en) 2025-12-11

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18742575T Active ES3048696T3 (en) 2017-07-05 2018-07-05 Ror1 antibodies

Country Status (11)

Country Link
US (3) US11466083B2 (enExample)
EP (1) EP3649152B1 (enExample)
JP (1) JP7242573B2 (enExample)
CN (1) CN110891973B (enExample)
AU (1) AU2018297630B2 (enExample)
CA (1) CA3068196A1 (enExample)
DK (1) DK3649152T3 (enExample)
ES (1) ES3048696T3 (enExample)
GB (1) GB201710835D0 (enExample)
MX (1) MX2019015348A (enExample)
WO (1) WO2019008377A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20230416942A1 (en) * 2020-08-21 2023-12-28 Yale University Nanobody Compositions and Methods of Use of the Same
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
EP4209509A4 (en) * 2020-09-03 2025-03-19 Harbour Biomed (Shanghai) Co., Ltd ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
JP2023550628A (ja) * 2020-11-23 2023-12-04 スカウト バイオ， インコーポレイテッド 抗原結合分子およびその使用
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20240309116A1 (en) * 2021-07-23 2024-09-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
PE20251274A1 (es) * 2022-03-09 2025-05-14 Sanyou Biopharmaceuticals Co Ltd Molecula de union dirigida a ror1 y uso de la misma
CN119604529A (zh) * 2022-07-11 2025-03-11 翰森生物有限责任公司 抗体、其抗原结合片段及其药物用途
CN116836286A (zh) * 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
AU2024331841A1 (en) * 2023-08-31 2026-03-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
US9316646B2 (en) * 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US10752684B2 (en) * 2014-07-29 2020-08-25 Cellectis ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
AU2015313268B2 (en) 2014-09-08 2018-12-20 National Cancer Center Cancer-cell-specific antibody, anticancer agent, and cancer testing method
JP2017536341A (ja) 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
US20160208018A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
EP3253754B1 (en) 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
CA3011419A1 (en) 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
US11008318B2 (en) 2016-07-11 2021-05-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
AU2018271872A1 (en) 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and ROR1 or ROR2
TWI804499B (zh) 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
EP3645741A4 (en) 2017-06-25 2021-08-25 Systimmune, Inc. ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN117756946A (zh) 2017-11-03 2024-03-26 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Also Published As

Publication number Publication date
US11466083B2 (en) 2022-10-11
US20230220073A1 (en) 2023-07-13
JP7242573B2 (ja) 2023-03-20
US20200354448A1 (en) 2020-11-12
MX2019015348A (es) 2020-07-20
US20250066472A1 (en) 2025-02-27
WO2019008377A1 (en) 2019-01-10
EP3649152B1 (en) 2025-10-08
CN110891973B (zh) 2023-06-27
AU2018297630A1 (en) 2020-01-16
CA3068196A1 (en) 2019-01-10
CN110891973A (zh) 2020-03-17
DK3649152T3 (da) 2025-11-10
JP2020530272A (ja) 2020-10-22
GB201710835D0 (en) 2017-08-16
EP3649152A1 (en) 2020-05-13
AU2018297630B2 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
US20250066472A1 (en) Ror1 antibodies
ES2906361T3 (es) Anticuerpos biespecíficos para ROR1 y CD3
ES2666131T3 (es) Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral
ES2877080T5 (en) Binding molecules specific for cd73 and uses thereof
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
KR102453226B1 (ko) 항―axl 항체
CN105813654A (zh) Tem8抗体及其用途
EP2167542A1 (en) Neutralizing monoclonal antibody against human dll4
TW201623331A (zh) 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US20230348568A1 (en) Epstein-barr virus monoclonal antibodies and uses thereof
CN111018984B (zh) 抗ck8单克隆抗体及其应用
HK40071055A (en) Bispecific antibodies to ror1 and cd3
KR20250079007A (ko) 2가 cd47 결합 단백질
HK40017928B (en) Bispecific antibodies to ror1 and cd3
HK40017928A (en) Bispecific antibodies to ror1 and cd3
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
WO2025201493A1 (zh) Dll3结合分子及其用途
CN117843781A (zh) Cd138抗体及其应用
WO2022228514A1 (zh) 抗人白血病抑制因子抗体及其用途
CN111040033A (zh) 靶向肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用